Method for simplified shipping of clinical specimens and optional direct analysis

Abstract

A method for shipping clinical specimens lawfully, safely, cheaply, and easily without regard to some or all of the laws, rules, and regulations regarding samples that may contain infectious and / or etiologic agents. Optional method of direct analysis of shipped samples.

Description

[0001] 1. Field of the Invention[0002] The present invention relates to a method for the simplified shipping of clinical specimens, especially specimens that may contain an etiologic agent. The present invention further relates to the laboratory analysis of the shipped specimen, preferably directly upon receipt and without further substantial sample preparation.[0003] 2. Background of the Invention[0004] The laboratory analysis of human or animal material, including, but not limited, to excreta, secreta, blood and its components, tissue, and tissue fluids is a necessity of modern medicine for the purposes of diagnosis. Most if not all Americans are familiar with "blood tests" used to determine their cholesterol level, the presence or absence of various microorganisms, and, depending upon level of sophistication, phenotyping, genotyping, etc. Such analysis is also used in therapeutic drug monitoring (TDM), which determines the quantity of a drug in the blood. TDM is now routine for a...

AI Technical Summary

Benefits of technology

[0018] Thus, a preferred embodiment of the present invention is a method for the shipping of clinical specimens lawfully without compliance with at least one of the various State, U.S., and, for countries other than the U.S., foreign national, as well as any applicable international, laws, rules, and regulations regarding shipment of materials that may contain etiologic agents, thereby avoiding the increased costs associated with shipping according to such laws, rules, and regulations and providing a safer, simpler, cost-effective method for the shipment of such samples. In a further preferred embodiment, the method includes receipt of the shipped clinical specimen (i.e., the safe clinical sample) by a laboratory, and in a highly preferred embodiment further includes the direct laboratory analysis of the sample as received (or after minimal preparation such as centrifugation, concentration, evaporation, and / or filtration). With the method of the present invention it is envisioned that the remote laboratory testing of a clinical specimen that has been converted into a safe clinical sample can be accomplished quickly (for example, within one day or less) and more cheaply than is the current state of the art with great efficiencies being realized in both the safer, simpler, easier, and cheaper method of shipping and, if laboratory testing is included in the method, with the cheaper and easier testing of the sample by either direct injection into the testing apparatus or direct subjection to the analysis method (or injection or subjection after minimal preparation such as centrifugation, concentration, evaporation, and / or filtration). It is envisioned that, with respect to TDM, the present method model will become a benchmark, allowing for relatively inexpensive, accurate, reproducible overnight turnaround for standard and even esoteric laboratory test results, thereby increasing the effectiveness of medical treatment and avoiding problems associated with sub-optimal therapy.

[0020] In addition to alcohol, other water-miscible organic solvents may be used for the invention purpose described above, including acetonitrile, methanol, and 2-propanol, among others. In a highly preferred embodiment, the solvent used does not affect the clinical specimen in a way that would affect the laboratory testing procedure intended for the specimen. It is particularly noteworthy that the invention method allows the user to avoid, if desired, the use of more hazardous and reactive chemicals that are often used for inactivation of etiologic agents, including chemicals such as formaldehyde, formalin, paraformaldehyde, glutaraldehyde, peroxygen-based compounds, and halogen-releasing compounds.

[0021] Another preferred present invention method for converting a clinical specimen into a safe clinical sample, thereby converting the clinical specimen from a very expensive and somewhat complicated sample to ship into a very simple, safe, easy, cheap sample to ship, is passage of the clinical specimen through a sterilizing filter to render the specimen non-etiologic and non-infectious. In a highly preferred embodiment, the clinical specimen is passed through a sterilizing filter that possesses pores preferably no greater than 0.2 microns in size. As an example, in order to prepare a non-infectious, non-etiologic safe clinical sample for shipping according to the present invention, a particular volume (for example 1.00 ml) of a body fluid such as urine, plasma, cerebral spinal fluid, whole blood, serum, etc. is passed through a 0.2 micron sterilizing filter. Of course, larger and smaller pore sizes can be utilized (such as 1.0 micron, 0.8 micron, 0.6 micron, 0.4 micron, 0.3 micron, 0.1 micron, 0.05 micron, 0.005 micron, and lower), but preferably 0.2 micron and smaller are used. In this way, method instructions and equipment may be provided that allows one to render a clinical specimen that may or does contain an etiologic and / or infectious agent non-infectious and non-etiologic and also, importantly, allow for lawful shipment of e.g., the safe clinical sample without regard to at least one of the various laws, rules, and regulations regarding the shipment of specimens that may contain infectious or etiologic agents.

[0025] An important benefit of the present invention method for rendering a clinical specimen safe (i.e., non-infectious and non-etiologic), in addition to the lessened costs and requirements regarding lawful shipping, is that the sample, once rendered safe according to the present invention method (by solvent addition, filter sterilization, use of some other agent, heating, etc.), may be shipped without temperature control, meaning that traditional cooling with dry ice, etc. is not required when shipping the invention safe clinical sample. In this regard, dual savings are realized--the high cost and danger of shipping unsafe samples is avoided as is the high cost, regulatory burden, and difficulty of shipping samples that must be kept cold, for example with dry ice. Of course, temperature control may be used if desired, such as dry ice, ice packs, etc., and this is preferred for labile analytes.

[0026] In this sense, the present invention method of clinical specimen treatment (for example with a water-miscible organic solvent) so as to render the specimen safe followed by simple shipping lawfully without compliance with at least one of the various laws, rules and regulations regarding the shipment of, e.g., etiologic samples provides a new and useful method for shipping as well as a new and useful method that can capitalize on economies not previously recognized or utilized. In this way, the simple steps of adding, for example, alcohol to a clinical specimen, or filter sterilization, or a combination thereof, to render it safe followed by lawfully shipping the treated sample without regard to the laws, rules, and regulations that govern the shipment of, e.g., clinical specimens that may contain etiologic agents, provide a significant advance in the art not previously recognized. While it has previously been recognized that 70 vol. % denatured alcohol, heat, etc. can be used to inactivate etiologic agents and that filter sterilization can remove etiologic agents, it has not previously been recognized that if clinical specimens are so rendered prior to shipping they may then be shipped simply, lawfully, safely, cheaply, and easily without regard to the laws, rules, and regulations regarding shipment of etiologic specimens, and / or without regard to the maintenance of a certain temperature or general temperature control, such as cooling with dry ice, etc.

[0030] In a highly preferred embodiment, a further method is provided that combines the sample inactivation / shipping embodiment described above in combination with the direct analysis of the sample upon receipt at a laboratory. This model provides for highly effective and cost efficient shipping due to the non-etiologic and non-infectious nature of the sample and the lack of a requirement for temperature control (dry ice, etc.) while at the same time providing a sample that is "analysis ready," meaning that no further sample preparation is required prior to laboratory testing. In this way, a method is described that provides extremely simple and quick turnaround of laboratory test results for clinical specimens.

Problems solved by technology

One problem encountered in the laboratory analysis of clinical specimens is that oftentimes the laboratory where analysis is conducted is located apart from where samples are collected.

The transportation of a clinical and, especially, an infectious specimen is highly regulated, complicated and expensive because of safety issues, health concerns, Department of Transportation regulations, and various other laws, rules, and regulations of the States and the United States, and foreign countries.

Even when a shipper does not reasonably believe that a clinical specimen contains an etiologic agent, readying such a sample for transport remains burdensome, expensive, and requires staffing by individuals who are fully apprised of all shipping regulations and who possess documentation of ongoing participation in training programs.

Another problem caused by the transport or shipping of clinical specimens to a laboratory for analysis is the integrity of the sample being shipped.

If the sample is not maintained at a proper temperature during transport it is possible that the sample when analyzed is different from that when it was obtained, and that the results provided by the laboratory do not reflect the true state of the patients condition.

The incorporation of dry ice or cold packs in a package increases the weight and, hence the shipping cost.

What's more, because carbon dioxide is toxic, the transport of dry ice by aircraft adds significant regulatory burden.

Hence, the burden of precise compliance to all shipping regulations regarding etiologic agents, dry ice, etc. rests squarely on the shipper.

Further, the real cost of sample analysis is inflated because of the packaging material costs, shipping surcharges, staffing by highly-trained shipping specialists, etc.